 MYOS RENS Technology Inc. MYOS or the Company NASDAQ: MYOS, a biotherapeutics and bionutrition company and the owner of Fortetropin, a proprietary bioactive composition derived from fertilized egg yolk that helps build lean muscle, announced today, the publication of a study that evaluated the impact of Fortetropin on the rate of muscle protein synthesis in older adults. The peer reviewed study titled, Effects of Fortetropin on the rate of muscle protein synthesis in older men and women: a randomized, double blinded, placebo-controlled study, published in the Journal of Gerontology: Medical Sciences, reports results from a randomized, double-blind, placebo-controlled human clinical study involving 10 men and 10 women 60-75 years of age conducted by researchers at the University of California, Berkeley and the University of Arkansas for Medical Sciences. The study can be found here: 